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Structure and activation of pro-activin A
Xuelu Wang1, Gerhard Fischer1 & Marko Hyvo¨nen1
Activins are growth factors with multiple roles in the development and homeostasis. Like all
TGF-b family of growth factors, activins are synthesized as large precursors from which
mature dimeric growth factors are released proteolytically. Here we have studied the
activation of activin A and determined crystal structures of the unprocessed precursor and of
the cleaved pro-mature complex. Replacing the natural furin cleavage site with a
HRV 3C protease site, we show how the protein gains its bioactivity after proteolysis and is as
active as the isolated mature domain. The complex remains associated in conditions used for
biochemical analysis with a dissociation constant of 5 nM, but the pro-domain can be actively
displaced from the complex by follistatin. Our high-resolution structures of pro-activin A
share features seen in the pro-TGF-b1 and pro-BMP-9 structures, but reveal a new oligomeric
arrangement, with a domain-swapped, cross-armed conformation for the protomers in the
dimeric protein.
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A
ctivins, members of transforming growth factor b
(TGF-b) superfamily, were first isolated from porcine
ovarian follicular fluid and identified as activating factors
for the release of follicle stimulating hormone1. Different
additional roles have since been identified for these proteins,
including regulation of embryogenesis, development of the
reproductive system, wound healing, stem cell differentiation
and regulation of immune response2–5.
Activins are disulfide-linked homo- and heterodimers of four
inhibin b chains. Activins A and B (homodimers formed from
inhibin bA and bB chains respectively) are the best characterized,
while the functions of inhibin bC and bE are poorly understood6,7.
Activins function both in autocrine and paracrine manner. They
conduce signalling by binding to extracellular domains of type I
and type II receptors and allowing the kinase domains of type II
receptors to phosphorylate those of type I receptors and initiate
the intracellular signalling8. Type I receptors in turn
phosphorylate Smad family of transcription factors, which
translocate to the nucleus and activate appropriate target
genes9. Activin signalling can be regulated by antagonist
follistatin and FSTL-3, both of which interact directly with
activins, blocking their interactions with receptors and thus
inhibiting the signalling process10,11.
Activins, like all other members in the TGF-b superfamily, are
synthesized as larger precursors. The precursor chain consists
of an N-terminal signal peptide, a poorly conserved pro-domain
of 250–350 residues and a smaller, but much more conserved
mature domain. Two precursor chains are typically disulfide-
linked through conserved cysteine residues in the mature
domains to form covalent dimers. In the case of TGF-b1, also
the pro-domains are cross-linked through cysteines. During the
secretory pathway, the precursors are processed by furin-like
proteases that cleave the polypeptide after a dibasic recognition
sequence between the pro- and mature domains, releasing the
mature signalling domain from the covalent linkage to the
pro-domain12. Mutations of this furin site have demonstrated
the necessity of cleavage for activation of the growth factors13, but
there are no examples of analyses of the same protein before and
after the proteolytic processing, studying the direct effect of the
cleavage on the structure and activities of the protein.
The pro-domains play important roles in the biosynthesis,
stabilization, transportation and signalling of the growth factors
and they have been shown to be essential for the assembly and
secretion of dimeric TGF-b1 and activin A14. The conserved
hydrophobic motif at the N-terminus of the pro-domains has
been identified as the key interface that stabilizes the mature
domains during synthesis15. Association with pro-domains
appears also to extend the in vivo half-life time of the mature
growth factors16,17 and the pro-domains have been reported
to interact with various extracellular matrix (ECM) molecules,
facilitating storage and, in some cases, modulating the activation
of the mature growth factors in the ECM18–20. A number of
disease-causing mutations have also been identified in different
pro-domains, highlighting their essential role in the biology of
these growth factors21.
The pro-form of TGF-bs is the best understood example of
these proteins. Its structure has shown how the pro-domains
dimerize through disulfide linkage and form a latent complex
with the mature growth factor22. In a cellular context the
N-termini of the pro-domains are disulfide-linked to the ECM
through latent TGF-b-binding proteins (LTBPs)23, locking the
growth factors into the matrix for later activation. Further
stimulation, such as integrin-mediated mechanical force, can
release the active growth factor from the stronghold of the pro-
domain24. But not all pro-domains interact with their mature
growth factors with such affinity and bind to ECM like pro-TGF-
bs. Pro-activin A has shown signalling activity once it has been
proteolytically cleaved13 and instead of an integrin-binding RGD
motif, the pro-domain has a Lys-rich region that can bind to the
heparin or heparan sulfate chains of proteoglycans19. Whether
the pro-domains are anchored in the ECM or circulate either
alone or with the mature growth factor after secretion is still
not clear.
The two published structures of precursor growth factors,
pro-TGF-b1 and pro-BMP-9, show large structural variation in
their quaternary structures22,25. Combined with the poor
conservation of the pro-domains, it is difficult to transfer this
structural information to other TGF-b superfamily members.
Attempt to model pro-activin A based on the structure of
pro-TGF-b1 has failed, while the model built from the structure
of pro-BMP-9 lacks the structural details of the N-terminus of the
pro-domain17. The flexibility of mature activin A complicates the
modelling further10.
We have studied the structure and activation of pro-activin A
in fine detail using an engineered version of the protein. This
enabled us to activate it proteolytically in vitro and study the
effect of this activation on the structure and function using
biochemical, biophysical and structural techniques. The crystal
structures we have determined of pro-activin A provide insights
into the variable features of the pro-domains in the TGF-b
superfamily and analysis of follistatin binding to the pro-complex
provides us with a further understanding of the role of this
inhibitor.
Results
Production and activation of human pro-activin A. Since its
original isolation from porcine ovarian follicle fluid, activin A has
been produced mainly in eukaryotic expression systems14,26–30.
To facilitate structural studies, we have established a method for
the production of recombinant human pro-activin A by refolding
from Escherichia coli produced material. We have engineered the
protein to enable proteolytic activation in vitro, by replacing the
original furin cleavage site with a HRV 3C protease site and
removed two N-terminal cysteine residues, which by analogy to
pro-TGF-b1 are likely to interact with the ECM, to avoid
interference with native disulfide structure of the rest of the
protein. Using an optimized protocol adapted from what we use
for mature activin A10, we were able to refold all variants of
pro-activin A efficiently and purify them to homogeneity.
Uncleaved pro-activin A shows the expected molecular weight
of a dimeric disulfide-linked protein in non-reduced SDS–
polyacrylamide gel electrophoresis (PAGE) and the correct
monomeric molecular weight when analysed under reducing
conditions (Fig. 1a). Size-exclusion chromatography in combina-
tion with multiple-angle light scattering (SEC-MALS) analysis
shows that pro-activin A is a single species with the expected
molecular weight (91.5 kDa, calculated molecular weight
90.9 kDa) (Fig. 1a). This uncleaved pro-activin A precursor is
unable to induce the expression of an activin-inducible luciferase
reporter gene in HEK293T cells (Fig. 1c), in agreement with
previous findings that cleavage is required for bioactivity13. As we
had engineered an HRV 3C protease cleavage site into our
protein, we could mimic the furin processing of pro-activin A
in vitro. After the protease treatment, pro-activin A migrated as
two distinct bands in SDS–PAGE. The pro-domain migrated as a
monomeric protein under both reducing and non-reducing
conditions, whereas the mature domain migrated as a disulfide-
linked dimer in a non-reduced gel, and converted into
monomeric species on reduction. SEC-MALS analysis shows
that after the cleavage the pro- and mature domains remain
associated with each other, eluting at the same volume as the
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uncleaved protein and showing dimeric molecular weight of
88.3 kDa (Fig. 1a).
In contrast to the uncleaved precursor, the cleaved pro-activin
A complex is highly active in the cell-based luciferase assay with a
half-maximal response concentration (EC50) of 29±3 pM (all the
EC50 and IC50 values and their s.d. values are determined from
three replicates). To evaluate the effect of the pro-domain on the
bioactivity, the mature domain was purified using reverse phase
chromatography, and its bioactivity was compared with an
identical protein that was produced without a pro-domain10
(Fig. 1b). The complex-derived mature activin A conducts
signalling marginally better than the pro-mature complex, with
an EC50 value of 20±2 pM, which is in excellent agreement with
the activity of our control activin A (EC50¼ 21±2 pM; Fig. 1c).
These data confirm that the refolded and proteolytically cleaved
pro-activin A is correctly folded, homogenous and fully
biologically active and that the pro-domain has only a marginal
effect on the bioactivity.
To understand the activation process of pro-activin A better,
we measured the affinity between the pro-domain and the mature
activin A using biolayer interferometry (BLI)31. The reverse phase
purified pro-domain was immobilized onto biosensors using its
N-terminal His6-tag and interaction with the mature activin A
was analysed by immersing the sensors into solutions with
mature activin A. This allowed us to determine both association
and dissociation constants for these binding events and to derive
a Kd value of 5.0±0.2 nM (all the Kd values and their s.d. values
are determined from two replicates; Fig. 1d). We determined the
affinity also by immobilizing the pro-mature complex onto the
same biosensors, removing mature domain from the complex
under non-denaturing conditions and measuring the binding as
before. This resulted in a similar dissociation constant of
2.3±0.1 nM, in good agreement with the affinity measured
using reverse-phase purified pro-domain (Supplementary Fig. 1).
With low nanomolar affinity, and considering the EC50 of 20–
30 pM, it is likely that the pro-activin A complex has mostly
dissociated at the concentrations required for full bioactivity. This
explains the only marginally lower bioactivity we measured for
pro-activin A complex in comparison with mature activin A in
our cellular assay. What we do not know is whether in vivo the
pro-domain associates with other molecules that might stabilize
the complex and thus affect the bioavailability of the mature
growth factor.
Crystal structure of pro-activin A. To understand the atomic
details of the interaction between the pro-domain and the mature
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Figure 1 | Characterization of pro-activin A and its activation. (a) SEC-MALS analysis of pro-activin A. Size exclusion chromatogram of purified uncleaved
pro-activin A (pro-ActA) precursor (black line) and cleaved pro-mature complex (red line) and molecular weight analysis (similarly coloured diamonds)
from light scattering for the top of the eluted peak with molar mass scale shown in the left Y axis and refractive index (RI) values in the right Y axis.
Peak fractions of each sample are analysed under reducing and non-reducing conditions using SDS–PAGE, shown in the inset (lanes of samples without
protein have been removed from the figure). (b) Separation of pro- and mature domains of cleaved pro-activin A using reverse phase chromatography.
SDS–PAGE analysis of the three peaks is shown in the inset, both under reducing and non-reducing conditions (lanes of samples without protein have been
removed from the figure). (c) Bioactivity assay of activins. Analysis of bioactivity of control activin A (blue markers and dose response curve), mature
activin A purified as in b (black), pro-activin A complex (red) and uncleaved pro-activin A precursor (green) using activin A inducible luciferase assay.
Data are average of three replicates, normalized to Renilla luciferase and scaled to 100% of maximum signal. The error bar shows the s.d. of each data point.
(d) BLI analysis of pro-domain binding to mature activin A. Coloured curves show the raw data with the concentration of activin A shown at the side of the
graph. The black lines show the fitted data.
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activin A, we determined the crystal structures of both the cleaved
and uncleaved forms of the protein. While the precursor form
described above crystallized, we were unable to increase the
diffraction beyond B50Å resolution. To improve the quality of
the crystals, we removed residues 259–282 (reported to be part
of heparan sulfate-binding site19) from the pro-domain. This
deletion did not affect folding of the protein and had no effect on
the bioactivity of the protein (Supplementary Fig. 2).
The resulting protein yielded significantly better diffracting
crystals, enabling us to determine its structure using multi-
wavelength anomalous dispersion phasing with selenomethio-
nine-labelled protein. We solved the structure of pro-activin A
precursor at 3Å and refinement of this structure against higher
resolution native data yielded a final structure at 2.3 Å. The
structure of the cleaved pro-activin A complex was determined at
2.85Å by molecular replacement using the precursor structure as
our starting model. Both structures are highly similar
(Supplementary Fig. 3), suggesting that the cleavage does not
result in significant changes in the structure of the complex, as
has been observed with pro-TGF-b1 (ref. 22). We will therefore
use the higher resolution precursor structure in the subsequent
analyses.
The structure of the pro-activin A precursor consists of two
subunit chains that are disulfide-linked at the mature domains
(Fig. 2a). In each subunit, the N terminus of the pro-domain,
starting from the first visible residue Q51, forms a helical
‘forearm’ region consisting of three a-helices (a1, a2 and a3),
a latency lasso and a b-hairpin. The structure continues then
across the dimeric mature domains, connecting to the globular
b-stranded ‘shoulder’ domain of the pro-domain. The linker
between the pro- and mature domains, with the protease cleavage
site, is visible neither in the precursor nor in the pro-mature
complex. Given the positioning and distance (B16Å) between
the end of the pro-domain and the start of the mature domain
(which is clearly defined), the connectivity shown in Fig. 2a is the
only feasible one; the alternative connectivity would require the
linker to wrap around the complex and even as a linear distance
(36Å) this is too long for the missing 10 residues to span.
In the structure of pro-activin A, two precursor chains form a
cross-armed, domain-swapped dimer. The ‘forearm’ regions wrap
around the mature domains and create a connecting ‘bridge’ to
the globular ‘shoulder’ parts, which in turn interact with the
opposite mature domains (Fig. 2b). The helical bridge connecting
the forearm and shoulder is clearly visible in the density map and
Shoulder
a b
90°
ProdomainProdomain
Mature
domain
Mature
domain
Furin site
Latency
lasso
α2
α3
β-hairpin
α4
α5
β1
β2β3
β4
β5
β6
NC
Latency
lasso Forearm
β2
β1
β8
β6β3
β4 β5
β7
Δ259-282Δ259-282
α1
β3
Shoulder Forearm
α3
α3
β-hairpin
α2
β-hairpin
α2
β1
β8β6
β4
β5
Forearm Shoulder
c d ActA with
ARIIb-ECD
(1NYS), 50°
C244
C247
C156
C237
C223C225
Pro-activin A
Pro-BMP-9
Pro-TGFβ-1
α6
α6
ActA with
pro-domain,
(5HLY), 75°
ActA alone
(2ARV), 90°
ActA with FST-315
(2P6A), 108°
TGFβ-1 with
pro-domain
(3RJR), 121°
BMP-9 with
pro-domain
(4YCG), 116°
Figure 2 | Structure of pro-activin A. (a) Quaternary structure of pro-activin A with mature domains coloured in darker and paler orange and pro-domains
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electron density. (b) View perpendicular to a, along the two-fold axis, showing the b-hairpins and the connecting a-helices that run over the mature domain
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(purple) with insets showing the differing disulfide bonding at the tip of the domain. (d) Superpositioning of different mature activin A structures, as
labelled in the figure. All the structures are aligned with one protomer only to the apo-structure of mature activin A. The apo-activin A dimer (orange) is
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dimer, defined as the angle between two Ile100m residues with the inter-chain disulfide bond as the origin.
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the anomalous difference map confirms the position of the
selenomethionines in the a3-helix (Supplementary Fig. 5). This
organization is in clear contrast to the structures of pro-TGF-b1
(PDB: 3RJR)22 and pro-BMP-9 (PDB: 4YCG)25, in which both
the forearm and shoulder parts of the pro-domains interact
with the mature domain of the other precursor chain in the dimer
(see Discussion below).
The shoulder domain of pro-activin A is very similar to those
of pro-TGF-b1 and pro-BMP-9, defined by two anti-parallel
b-sheets and an a-helix (Fig. 2c). The two cysteines in the pro-
domain of activin A form an intra-chain disulfide bond (instead
of the inter-chain disulfide bonds found in pro-TGF-b1)
connecting the a6-helix with the preceding loop; equivalent
disulfide in pro-BMP-9 bridges two neighbouring b-strands.
Variable conformation of mature activin A. The structure
of mature activin A has been determined a number of times,
in isolation10 and in complex with receptor ecto-domains32,33,
follistatins34,35 and FSTL-3 (ref. 11). In these structures the
mature activin A dimer shows significant variation in its
inter-protomer conformation, more than any other TGF-b-like
ligand10. The inter-protomer angle of dimeric activin A ranges
from 50 to 108 (Fig. 2d). Even the most linear, antiparallel
conformation for activin A (in complex with FST-315) is still not
as open as other ligands, such as TGF-b1, with an inter-protomer
angles of 108 and 121, respectively. TGF-b3 has also been
reported to show conformational changes when it is complexed
with receptors36, but to a much lesser extent (115–125)
compared with activin A.
In the pro-activin A, the mature domain shows more closed
conformation (75) than in most other structures, and much
more so than TGF-b1 or BMP-9 in their pro-complexes
(Supplementary Fig. 6). Crystal packing could cause some of
these variations, but it is clear that activin A is highly malleable
and this property has been proposed to play a role in the
interaction with its type I receptors33.
The palm a-helix of the mature domain appears to be
disordered in both pro-domain structures, lacking interpretable
electron density (Supplementary Fig. 4a). This helix is also
missing from the complex of mature activin A with type II
receptors where the dimer shows highly closed conformation
(50, PDB: 1NYS)32. The closed conformation in both cases
causes the connecting loop from the end of the helix (Met68m) to
the start of the next b-strand (Cys81m) to pull the helix from the
dimer interface. Whether this is also happening in solution,
remains to be determined.
Structure of pro-activin A reveals a new connectivity. The
cross-armed conformation of pro-activin A is different from
the closed ring-shaped conformation in pro-TGF-b1 and the
widely open conformation in pro-BMP-9 and the connectivity in
pro-activin A is different too (Fig. 3a–c)
The structure of pro-activin A shows a continuous polypeptide
chain in the protomeric precursor chain with the exception of
the loop between b4 and b5 strands, the activation loop and the
mature domain a-helix (Supplementary Fig. 4a). Although the
electron density for the linker between the pro-domain and
the mature domain (Glu301-Arg310) is not visible, it has been
confirmed to be intact by SDS–PAGE analysis of dissolved
crystals (Supplementary Fig. 4b). One of the key features of the
oligomeric architecture is the connection between the forearm
region and the shoulder domain. Unambiguous electron density
shows how the pro-activin A forearm region is connected by a
long a-helix to the shoulder domain that sits on the top of the
opposite mature domain (Fig. 3a). In contrast, the structure of
pro-TGF-b1 appears to be in a different oligomeric arrangement
with the forearm and shoulder of one pro-domain interacting
with the mature domain from the other chain22 (Fig. 3b).
However, the electron density for the loops (Glu62-Pro68)
between forearm and shoulder region are not visible in the pro-
TGF-b1 structure and the connectivity cannot be unambiguously
defined. Given the similarity of the pro-activin A structure, it is
tempting to speculate that pro-TGF-b1 has in fact the same cross-
armed structure as pro-activin A. The distances between Glu62
and Pro68 in the pro-TGF-b1 structure are B15Å if connected
as in the original structure and B17Å if the connectivity would
be the same as for pro-activin A (Supplementary Fig. 7a,b), and
both arrangements are therefore possible. In the structure of
pro-BMP-9, the end of the a2-helix is very close to the start of the
shoulder part and it could not be connected in the same way as
pro-activin A is.
Implications on other TGF-b precursors. Despite the highly
divergent overall conformations, the protomeric subunits of
pro-activin A, pro-TGF-b1, and pro-BMP-9 share many features
and comparison of these structures allows us to predict some
common structural features in the TGF-b superfamily.
The a1- and a2-helices and the latency lasso in the forearm
region of pro-activin A form a hydrophobic interface with the
mature domain (Fig. 3d), as in the structure of pro-TGF-b1
(Fig. 3e). A notable difference between these two structures is the
disorder of the a-helix from the palm region of the mature
domain in activin A, with the a1-helix of the pro-domain is
occupying this position. The a2-helix of pro-activin A has a
slightly different orientation compared with that of pro-TGF-b1
and makes hydrophobic contacts with the following b-hairpin
(which is not present in pro-TGF-b1). Despite these differences,
the hydrophobic residues in the forearm that define the interface
with the mature domain are well conserved between pro-activin
A and pro-TGF-b1. In the structure of pro-BMP-9, the a1-helix is
replaced by a5-helix in the concave site of the mature domain
and therefore cannot be compared directly. Structure-based
sequence alignment of the selected members of the TGF-b
superfamily reveals a conserved hydrophobic motif in the forearm
region (Supplementary Fig. 8). High sequence similarity in the
regions of a1- and a2-helices and the fully conserved leucine and
proline residues in the latency lasso suggest a common interface
between the pro-domain and the mature domain in different
members of the TGF-b family.
The core of the globular shoulder domain of the pro-domain is
also well conserved between the three structures (Fig. 2c). One of
the b-sheets extends to the mature domain, forming an extended
b-sheet in pro-activin A and pro-BMP-9 structures. In pro-
activin A, this extended b-sheet is further strengthened by
Glu139, Ser141 and Glu143 from the shoulder domain making
polar contacts with Asp95m, Asn99m and Lys103m from the
mature domain (Fig. 3g). A similar extended b-sheet presents in
the structure of pro-BMP-9, but it lacks the additional polar
contacts and the interaction between the b-strands in the
pro-domain and the mature domain appears less intimate
(Fig. 3i). In pro-TGF-b1, the b-sheet of the pro-domain is
rotated about 90 from the mature domain and adopts a vertical
conformation, constrained by the inter-chain disulfide bond at
the bowtie regions (Fig. 3h).
Regulation of pro-activin A by follistatin. Follistatin (FST) is a
well-studied antagonist of activins and the mechanism by which it
inhibits activin A signalling has been well characterized10,34. Its
ability to inhibit pro-activin A is less well known and we have
therefore analysed the ability of FST to interact with pro-activin
A. Follistatin is found in two main isoforms, follistatin-288
(FST-288) and follistatin-315 (FST-315), as a result of alternative
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splicing of the last exon37, both of which can inhibit activin
signalling34,35. FST-288 has been reported to be more efficient in
the inhibition of activin A signalling with a Kd of 46.5±0.37 pM
(ref. 38) and we have therefore used this shorter isoform in our
studies.
In the luciferase-based bioassay, with pro-activin A complex
and mature activin A at the concentration of 60 pM, FST-288
inhibited the signalling of both the pro-mature complex and the
mature dimer, with IC50 values of 90±9 and 81±3 pM,
respectively (Fig. 4a). This demonstrates that the pro-domains
do not seem to affect the ability of FST-288 to inhibit activin A.
To understand whether FST-288 forms a complex with the pro-
domain-associated activin A or with the mature domain only, we
analysed activin–follistatin interaction by co-immunoprecipita-
tion with 200 nM pro-activin A complex (40 above the
dissociation constant of 5 nM) and 1.2 mM FST-288, capturing
the pro-domain with its N-terminal His6-tag (Fig. 4b). Without
FST-288, the mature domain activin A can be co-precipitated
with the pro-domain, as expected. When FST-288 was mixed
with the pro-activin A complex, only the pro-domain was
observed in the precipitant, suggesting FST-288 binds only to the
mature activin A and competes with the pro-domain. In a reverse
experiment we used an anti-FST-288 antibody to precipitate
FST-288 and any proteins bound to it. In this case, the
pro-domain remained in solution and only the mature protein
was precipitated with FST-288 (Fig. 4c), confirming that FST-288
binds only to the mature activin A and displaces the pro-domain
from its complex with the mature domain.
As shown earlier, the binding affinity between the pro- and
mature domain is relatively modest at 5 nM. The displacement of
pro-domain by FST-288 could thus be due to the dissociation of
the pro-activin A complex, with FST-288 binding to the released
mature domain, rather than through active competition with
pro-domain. To distinguish between these two models, we
measured the dissociation rate of the mature activin A from the
pro-domain in the presence and absence of FST-288 (Fig. 4d).
His6-tagged pro-activin A complex was immobilized on sensor
tips through the pro-domain at different concentrations and then
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Figure 3 | Comparison of pro-activin A with pro-TGF-b1 and pro-BMP-9. (a–c) Structures of pro-activin A (green pro-domains), pro-TGF-b1 (blue) and
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immersed either into buffer alone or into buffer containing
100 nM FST-288, monitoring the dissociation of the mature
domain in both cases. The dissociation was clearly faster in the
presence of FST-288 for all levels of immobilized pro-activin A
complex (Fig. 4d), with the dissociation rate increasing from 2.99
(±0.02) 10 3 to 4.45 (±0.02) 10 3 s 1 (these dissociation
rates and their s.d. values are determined from two replicates),
indicating that FST-288 can actively displace the pro-domain and
extract mature activin A from its grip. This suggests that
follistatin can exert its inhibitory effect on activin A even when
the mature domain is complexed with its pro-domain, by
dissociating this complex and binding to the mature dimer.
Given the binding mode of follistatin, where one follistatin
interacts with one side of activin A dimer, we speculate that
dissociation of one N-terminal pro-domain epitope on the mature
activin A could allow follistatin to compete for this site and
prevent re-binding, and thereby promote dissociation of the
second pro-domain and complete separation of pro- and mature
domains. Follistatin binds also to myostatin, but with a slightly
lower affinity (12.3 nM) (ref. 39). The affinity between myostatin
pro- and mature domains is very similar (8.3 nM) to what we
have determined for pro-activin A complex20 and we would
predict that follistatin can act on myostatin pro-mature complex
in a similar way as it does on activin A.
As uncleaved pro-activin A is biologically inactive, it was not
possible to analyse its interaction with FST-288 using the
luciferase-based bioassay and we characterized this interaction
using BLI. Avi-tagged FST-288 was immobilized on streptavidin
biosensors and interactions were analysed by monitoring binding
to different forms of activin A (Fig. 4e–g). The response curves of
FST-288 binding to the mature activin A and cleaved pro-activin
A complex reached the equilibrium very quickly at 25 nM analyte
concentration, resulting in very similar Kd values of 209.0±0.6
and 258.6±1.2 pM, respectively. Similarly to the bioactivity
assays, most of the pro-domains will have dissociated from
the mature domains, with pro-domains having only modest
inhibitory effect on FST-288 binding. The association rate of
FST-288 binding to pro-activin A precursor, however, was very
slow and the response did not reach the plateau in the association
phase even at 2mM analyte concentration, suggesting that the
covalent linkage between the pro-domain and mature domain in
pro-activin A precursor hinders FST-288 binding and prevents it
from displacing the pro-domain from the mature domain.
The pro-domain covers receptor and follistatin binding sites.
The pro-domain has been shown to have an inhibitory effect on
activin A signalling at high concentrations, with an IC50 value
around 100 nM (refs 15,28). The structure of pro-activin A
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12052 ARTICLE
NATURE COMMUNICATIONS | 7:12052 |DOI: 10.1038/ncomms12052 | www.nature.com/naturecommunications 7
provides support to these findings. It shows that the receptor-
binding surfaces of activin A are covered by the pro-domain
(Fig. 4h,i). The hydrophobic residues (Leu83, Ile87, Leu90, Val92,
Ile103 and Ile107) on the forearm region of the pro-domain
interact with the residues in the type II receptor-binding epitope
(Fig. 3d). It is apparent that binding of the pro-activin A complex
to the type II receptor requires displacement of the pro-domain,
consistent with the findings in previous studies15. Since the
covalent linkage between the pro-domain and the mature domain
is not in the way of the type II receptor-binding site, the inability
of the pro-activin A precursor to induce signalling suggests the
linkage may hinder type I receptor binding and hence inhibit the
signalling.
Similarly, all the key FST-288 binding sites are also occupied by
the pro-domain (Fig. 4h,i). The forearm region of the pro-domain
covers the convex surface of the mature activin A that binds to
follistatin domain 1 and 2 (FS12) and the a1-helix of the
pro-domain occupies the concave surface of the mature activin A
that binds the a-helix of follistatin N-terminal domain. The
groove between the two fingertips of activin A is occupied by the
pro-domain latency lasso and the side chain of Arg71 forms a salt
bridge with Asp27m of the mature activin A, which in turn makes
polar contact with Arg192 in complex with follistatin. The
fingertips of activin A also adopt a different orientation due to
formation of the extended b-sheet with the pro-domain.
Discussion
We have shown using highly purified pro-activin A how the
cleavage between the pro- and mature domains fails to dissociate
the complex at moderate concentrations, yet it renders the growth
factor fully active in our bioassays. In our previous research, we
found mature activin A is poorly soluble in physiological buffers
and tends to aggregate readily10. In contrast, the pro-activin A
complex is highly soluble, and amenable to purification in native
conditions. It is therefore conceivable that one of the biological
roles for the pro-domain is to facilitate the solubility and in vivo
distribution of the mature growth factor, reducing unwanted
interactions and delivering the protein to the site of action.
Activins and BMPs act as morphogens in developing embryos.
Diffusion of these proteins in the embryonic tissues has been
studied, but mainly using mature domains only and by detecting
their activity in the responsive cells40. The role of the pro-domain
is less well understood, even ignored, and more work is needed to
understand this fully.
It has been suggested that the pro-domains promote the
synthesis and assembly of mature growth factors, acting as
molecular chaperones14. These claims usually stem from the
notion that deletion of the pro-domain prevents the mature
domain from being secreted from the cells. There are many
reasons why such deletion could affect secretion of the mature
domain, and direct evidence for the chaperone function is
missing. With our new structures of pro-activin A, and the
revised connectivity of the complex, the chaperone function
seems more compelling (Supplementary Fig. 9). The forearm
region with the latency lasso could be stabilizing the mature
domain of the same polypeptide in a conformation that is
compatible with dimerization, while protecting the largely
hydrophobic surfaces that bind the receptors. This monomeric
protein with its uncomplexed globular shoulder domain is then
free to find another monomer in the endoplasmic reticulum to
dimerize with. The shoulder domain can interact with the fingers
of the opposing mature domain, which are in turn protected by
its own forearm epitopes. This mechanism would also be well
posed to facilitate dimerization of the growth factors, as
individual chains are able to fold more completely and obtain a
conformation that is compatible with dimerization. The
connectivity and interactions between the pro- and mature
domains could determine dimerization propensity as only
mutually compatible monomeric pro-forms could interact with
each other in either homo- or heterodimeric manner.
The role of pro-domain in confirming latency to the TGF-bs is
well understood and this is largely due to the additional
interaction between the pro-domain and the ECM. There is
significant evidence that other pro-domains also interact with
the components of the ECM, and activin A pro-domain is
known to bind to heparan sulfates. These interactions can act
as additional glue that keep the pro-domains together, or
immobilize them to a desired location in vivo, and thus affect
the activity of the growth factors. Intriguingly, like TGF-bs,
activins, myostatin (GDF8) and GDF11 contain additional
cysteines in the N-termini of their pro-domains and these are
likely places for immobilization to the ECM, or for interactions
with other proteins. Myostatin is thought to interact with LTBP1,
but no data are available for activin A. Johnson et al.17 have
recently shown that pro-activin A is secreted from HEK293F
cells as soluble complex, but identification of stoichiometric
disulfide-bonded partners would require the components to be
expressed at similar levels, and understanding these interactions
will require the analysis of proteins in their natural context and in
physiological concentrations, as has been done with latent-TGF-b
(refs 41,42).
In addition to understanding the physiology of these growth
factors, the pro-domain complexes offer great opportunities for
engineering new functions to these growth factors and to regulate
them in the extracellular milieu. A chimeric pro-domain
consisting of the N-terminal region of activin A pro-domain
and the C-terminal region of TGF-b1 pro-domain has been used
as an inhibitor for activin A28, reflecting the shared mechanism
that these proteins interact with the mature domains, and the
different levels of regulation/latency they confer to the mature
growth factor. Undoubtedly more such engineering will be
inspired by the analysis of these structures.
Methods
Pro-activin A constructs and protein expression. The construct of human
inhibin bA chain (residues 30–426, Uniprot P08476) was cloned by PCR into
pHAT2 expression plasmid, with resulting fusion gene encoding the subunit of
human pro-activin A with an N-terminal His6 tag. Mutagenesis to introduce the
HRV 3C protease site and to remove the lysine-rich loop was performed by
two-step PCR protocol using overlapping oligonucleotide across the mutated
region; all oligonucleotides used for cloning are listed in the Supplementary
Table 1.
The expression constructs were transformed into competent cells
BL21(DE3)þ pUBS520, grown overnight at 37 C on LB-agar plates containing
100 mgml 1 of ampicillin and 25mgml 1 kanamycin. Large-scale expression was
performed by inoculating 1 litre of 2YT media using colonies collected from
LB-agar plate that has been grown overnight at 37 C. Protein expression was
induced by 400mM IPTG at OD600 of 0.6–0.8 and carried out at 37 C for 4 h. Cells
were then pelleted by centrifugation at 5,020g for 20min and re-suspended in
MilliQ water and stored at  20 C.
Protein refolding and purification. The cell pellet from 1 liter of bacterial culture
was suspended in lysis buffer (50mM Tris-HCl pH 8.0, 0.5mM EDTA, 10mM
DTT) with 0.5% (v/v) Triton-X100 and lysed using the Emulsiflex C5 homogeniser.
The lysate was incubated with DNase I and 4mM MgCl2 for 20min at room
temperature before it was centrifuged at 15,000g for 20min to pellet the insoluble
inclusion bodies. The inclusion bodies were washed in lysis buffer with 0.5%
Triton-X100, followed with lysis buffer with 1M NaCl, and then with lysis
buffer only. The washed inclusion bodies were re-suspended in 5ml of 100mM
neutralized tris(2-carboxyethyl)phosphine (TCEP) and proteins were denatured by
addition of 15ml of solubilization buffer (8M guanidine hydrochloride (GndHCl),
50mM Tris-HCl pH 8.0, 10mM EDTA, 0.1M cystine), followed by 1-h incubation
at room temperature. Denatured solubilized pro-activin A sample was clarified by
centrifugation at 15,000g for 20min. Before refolding, the denatured protein was
buffer exchanged into 6M urea and 20mM hydrochloric acid, adjusted to
1mgml 1 and then diluted to the concentration of 0.1mgml 1 into cold
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refolding buffer (100mM Tris-HCl pH 8.0, 100mM ethanolamine pH 8.0, 1M
pyridinium propyl sulfobetaine, 0.5mM EDTA, 0.2mM cystine and 2mM
cysteine) with vigorously stirring. The refolding process was allowed to proceed for
7 days at 4 C.
Refolded protein solution was adjusted to pH 6.0 and was then loaded onto the
HiTrap SP HP 5ml column (GE Healthcare) that had been equilibrated with
50mM MES pH 6.0. The bound sample eluted with a linear gradient to 50mM
MES pH 6.0, 1M NaCl in 20 column volumes. Peak fractions with dimeric
pro-activin A were pooled and purified further by size exclusion chromatography
using HiLoad 16/600 Superdex 200 prep grade column (GE Healthcare) in 10mM
Tris pH 8.0, 500mM NaCl and 0.5mM EDTA pH 8.0. Reduced and non-reduced
SDS–PAGE was used to analyse the purified proteins.
Selenomethionine-labelled protein was expressed in minimal medium using
metabolic suppression method to minimized endogenous methionine production
and refolded and purified like the unlabelled protein. Selenomethionine
incorporation was confirmed to be complete by mass spectrometry.
For the production of cleaved pro-activin A complex, engineered pro-activin A
with its natural furin cleavage site replaced by HRV 3C cleavage site was mixed
with recombinant GST fused HRV 3C protease at a mass ratio of 5 to 1 and
incubated at 4 C for overnight. The cleaved pro-activin A was separated from
GST-tagged protease by passing the mixture through Glutathione Sepharose 4 Fast
Flow beads (GE Healthcare).
SEC-MALS analysis. SEC-MALS analysis was performed using a Superdex 200
Increase 10/300 column (GE Healthcare) connected to the DAWN HELEOS II
light scattering detector (Wyatt Technology) and the Optilab T-rEX refractive
index detector (Wyatt Technology). Bovine serum albumin (Thermo Scientific)
was used to calibrate the system in the elution buffer (10mM Tris pH 8.0, 500mM
NaCl) before 100 ml of protein sample at the concentration of 1.5mgml 1
was analysed. The experimental data were recorded and processed by ASTRA
(Wyatt Technology) software.
Co-immunoprecipitation. Pro-activin A complex and its mixture with follistatin-
288 (FST-288) were analysed by immunoprecipitation (IC) assay using Protein G
magnetic beads (ThermoFisher). A volume of 50 ml of the magnetic beads was
incubated with 10mg of penta-His antibody (Qiagen, catalogue no. 34660) to
capture the His6-tagged pro-domain of pro-activin A complex. The antibody-
bound magnetic beads were washed three times using phosphate-buffered saline
(PBS) and split into three tubes to be incubated with 200 nM pro-activin A
complex, 200 nM activin A or the mixture of 200 nM pro-activin A complex with
1.2 mM FST-288, respectively, for 30min at room temperature. Similar experiment
was performed using magnetic beads that were immobilized with anti-FST-288
antibody (Ansh Labs LLC, catalogue no. AB-307-AF002) at the same bead/anti-
body ratio. Three samples, 200 nM pro-activin A complex, 600 nM FST-288 or the
mixture of 200 nM pro-activin A complex with 600 nM FST-288 were mixed with
the antibody-bound magnetic beads. PBS with additional 400mM NaCl was used
to wash these magnetic beads three times to eliminate non-specific bound proteins.
The bound proteins were then eluted from the magnetic beads by 10mM glycine
pH 1.7 and analysed by SDS–PAGE. Uncropped figures of the SDS–PAGE analyses
are shown in the Supplementary Fig. 10.
Luciferase assay. To analyse the signalling activity of activin A in different
protein forms, a cell-based luciferase assay was established. HEK293T cells (ATCC,
catalogue no. CRL-3216; a generous gift from Dr Trevor Littlewood, Department of
Biochemistry, University of Cambridge) were cultured in 96-well flat-bottom
cell culture plates using Dulbecco’s Modified Eagle Medium (DMEM; Life
Technologies) with 10% (v/v) fetal bovine serum (FBS; Life Technologies) at 37 C
in a humidified incubator with 5% CO2. When the confluence of cells reached 80%,
33 ng of pGL3-CAGA (carrying activin A responsive firefly luciferase gene) and
17 ng of pRL-SV40 (Promega, with constitutively expressed Renilla luciferase)
plasmids were transfected into the cells in each well using 0.2 ml of FuGENE HD
transfection reagent (Promega). After overnight incubation, the cells were washed
with sterile PBS and cultured in DMEM with 0.5% FBS. Serial dilutions of activin A
and its pro-forms in DMEM with 0.5% FBS were added into the cell culture and the
experiments were performed in triplicate. In the FST-288 inhibition assay, FST-288
was diluted in DMEM containing 0.5% FBS and 60 pM activin A or pro-activin A.
The mixture samples were then added into the cell culture in triplicate. After
overnight incubation, cells were washed with PBS and lysed using 20 ml of passive
lysis buffer (Promega). A volume of 5 ml of cell lysate in each well was transformed
into Corning 96-well flat-bottom white plate (Sigma) and was mixed with 25 ml of
Dual-Glo Luciferase Reagent (Promega). After incubation with shaking for 30min,
the firefly luciferase was measured using PHERstar microplate reader (BMG
LABTECH). A volume of 25ml of Dual-Glo Stop & Glo Reagent (Promega) was
then added into each well to quench the signal from firefly luciferase and to provide
substrate for the Renilla luciferase. The luminescence was measured using BMG
PHERAstar microplate reader. The final response was normalized using the firefly
luminescent signal divided by the Renilla luminescent signal. Relative response
ratio was calculated as (RRmin)/(RmaxRmin) to allow numerical comparison
Table 1 | Crystallographic data collection and structure determination statistics.
Pro-activin A complex
PDB:5HLZ
Pro-activin A precursor
PDB:5HLY
SeMet pro-activin A
precursor
Data collection
Space group P31 P61 2 2 P61 2 2
Cell dimensions
a, b, c (Å) 47.2, 47.2, 445.4 46.6, 46.6, 444.9 47.0, 47.0, 448.1
a, b, g () 90.0, 90.0, 120.0 90.0, 90.0 120.0 90.0, 90.0, 120.0
Peak Inflection Remote
Wavelength 0.97949 0.97866 0.97949 0.97934 0.97204
Resolution (Å) 44.5–2.85 (3.01–2.85)* 74.15–2.30 (2.38–2.30)* 37.05–2.90 (2.91–2.90)* 37.05–2.90 (2.91–2.90)* 37.05–2.91 (2.92–2.91)*
Rsym or Rmerge 0.114 (0.948) 0.107 (0.687) 0.109 (0.575) 0.116 (0.627) 0.121 (0.549)
I/sI 9.7 (1.6) 17.3 (2.4) 17.5 (1.4) 17.3 (1.5) 16.1 (1.7)
Completeness (%) 99.9 (99.8) 79.3 (37.1) 83.7 (19.8) 84.0 (20.7) 83.0 (19.2)
Redundancy 5.1 (4.9) 14.3 (7.3) 10.9 (2.5) 10.9 (2.5) 11.0 (3.3)
Refinement
Resolution (Å) 40.90–2.85 74.15–2.30
No. of reflections 25,878 18,900
Rwork/Rfree 0.220/0.273 0.2025/0.2524
No. of atoms
Protein 9,153 2,380
Ligand/ion 0 1
Water 10 25
B-factors (Å2)
Protein 69.6 44.2
Ligand/ion NA 59.4
Water 49.3 35.4
r.m.s. deviations
Bond lengths (Å) 0.004 0.003
Bond angles () 0.810 0.724
*For each structure, a single crystal was used. Values in parentheses are for the highest resolution shell. NA, not applicable.
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between assays from different plates, where Rmin is the minimal response from the
negative control and Rmax is the maximal response from the positive control in
each plate.
Biolayer interferometry. To analyse protein interactions, biolayer interferometry
experiments were performed using Octet RED96 (ForteBio) instrument at 30 C.
The interactions between pro- and mature domain of activin A were analysed using
anti-penta-HIS biosensors immobilized with N-terminal His6-tagged pro-domain
or pro-activin A complex. The biosensors immobilized with pro-activin A complex
were dipped into blank buffer or buffer containing 100 nM FST-288 for 600 s to
measure the dissociation rate of the complex in different conditions. To analyse the
affinity between pro- and mature domains of activin A, biosensors immobilized
with pro-domains at 25mgml 1 were dipped into the solution containing mature
activin A at different concentrations for 300 s as the association phase and then
moved to the blank buffer for 300 s as the dissociation phase. Similar experiments
were performed using biosensors immobilized with pro-activin A complex at
50mgml 1. Before dipping into activin A solutions, the immobilized biosensors
were treated with 16mM FST-288 to scavenge all the mature activin A from the
pro-activin A complex on the biosensors. After 90 s of baseline stabilization, these
treated biosensors were dipped into solutions containing mature activin A for 600 s
and then into blank buffer for 600 s.
The interactions between FST-288 and activin A in different protein forms were
performed using streptavidin (SA) biosensors with the biotinylated FST-288
immobilized on the biosensors. To produce the biotinylated FST-288, 100 mg of
Avi-tagged FST-288 was incubated with 15 units of BirA enzyme in PBS buffer
containing 10mM ATP, 10mM magnesium acetate, 50mM D-biotin for 1 h at
30 C before the protein was purified by reverse phase chromatography and
vacuum-dried. The biotinylated FST-288 was then suspended in the kinetic buffer
(PBS, 0.1% bovine serum albumin and 0.02% Tween-20) to the concentration of
50mgml 1. Activin A, pro-activin A complex and pro-activin A precursor were
diluted in the kinetic buffer to the concentrations as shown in the experiments.
Before the experiment, the streptavidin sensors were regenerated 5 s in 10mM
glycine pH 1.7 for three times with neutralization in the kinetic buffer in between.
After measurement of 60-s baseline, the biotinylated FST-288 was loaded onto the
tips for 600 s after which the rest of the streptavidin-binding sites were blocked
with 100 mgml 1 biocytin (biotin–lysine conjugate) for 300 s. After further 120 s of
baseline stabilization, the association phase of the binding was performed for 600 s
and then followed by dissociation for 600 s.
The data were analysed and fitted by Prism 6 software (GraphPad) using kinetic
model as follows.
Dissociation model:
R ¼ R0e koff ðt t0Þ;
where R is BLI response, t is time, R0 and t0 are the starting response and time of
dissociation phase.
Association model:
R ¼ konCRmax
konCþ koff ð1 e
 konCþ koffð ÞtÞ;
where C is the concentration of analyte, Rmax is the maximum response at the
equilibrium with the maximum concentration of analyte.
Crystallization and structure determination. Engineered pro-activin A precursor
and complex with truncation of the Lys-rich region (K259-D282) were
concentrated to 15mgml 1 and used to set up 96-well crystallization plate using
Mosquito Crystal (TTP Labtech) crystallization robot. Crystals of engineered
pro-activin A precursor were obtained from sitting drops consisting of 200 nl
of protein and 200 nl of crystallization solution. Crystallographic data were
collected at beamline I04 at Diamond Light Source synchrotron using a mini-kappa
goniometer to improve the separation of diffraction spots on the detector.
Multi-wavelength anomalous dispersion data were collected under three wave-
lengths (0.9793, 0.9795 and 0.9720Å) from the crystal of selenomethionine-labelled
pro-activin A precursor with truncation of Lys259-Asp282, grown in 11.4% PEG
400, 12.9% PEG 2000MME and 100mM HEPES pH 7.1 at the protein con-
centration of 15mgml 1. A single-wavelength anomalous dispersion data set was
collected at a wavelength of 0.9793Å from the crystal of the same protein grown in
25% PEG 1000 and 100mM MES pH 6.5. A native data set was collected from a
crystal of cleaved pro-activin A complex with truncation of K259-D282, grown in
20% PEG 3350 and 200mM calcium chloride.
Raw data were indexed and integrated using XDS software43 and scaled using
Aimless in CCP4 suite44. Experimental phasing was performed using
autoSHARP45 and molecular replacement was performed using Phaser in CCP4
suite46. The model was manually corrected using Coot 0.8.1 (ref. 47) and refined
using Refmac5 (ref. 48) and Phenix49. The dihedral angles of 97.6% of all amino-
acid residues in the structure of unprocessed pro-activin A precursor are in the
favoured region and none of the residues in the non-allowed region. The dihedral
angles of 97.1% of all amino-acid residues in the structure of pro-mature activin A
complex are in the favoured region and none in the non-allowed region. All the
data collection, data reduction, structure determination and refinement statistics
are shown in Table 1.
Data availability. Coordinates and structure factors have been submitted to the
Protein Data Bank under accession numbers 5HLY for the unprocessed pro-activin
A precursor and 5HLZ for the pro-mature activin A complex. All additional
experimental data are available from the corresponding author on request.
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